s-nitrosoglutathione has been researched along with Invasiveness, Neoplasm in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deshpande, M; Giri, S; Graham, RP; Johnson, Z; Maguire, JL; Rattan, R; Shridhar, V | 1 |
| Baba, H; Beppu, T; Furuhashi, S; Horino, K; Miyake, K; Nakahara, O; Okabe, H; Sugita, H; Takamori, H; Tanaka, H | 1 |
2 other study(ies) available for s-nitrosoglutathione and Invasiveness, Neoplasm
| Article | Year |
|---|---|
Preclinical therapeutic potential of a nitrosylating agent in the treatment of ovarian cancer.
Topics: Administration, Oral; Animals; Biotin; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; DNA; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Intercellular Signaling Peptides and Proteins; Mice, Nude; Neoplasm Invasiveness; Nitrosation; Ovarian Neoplasms; Protein Binding; S-Nitrosoglutathione; Signal Transduction; STAT3 Transcription Factor; Tumor Stem Cell Assay | 2014 |
NO donor and MEK inhibitor synergistically inhibit proliferation and invasion of cancer cells.
Topics: Butadienes; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; HCT116 Cells; HT29 Cells; Humans; Insulin-Like Growth Factor I; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; Nitric Oxide; Nitric Oxide Donors; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; S-Nitrosoglutathione; Signal Transduction; Up-Regulation | 2012 |